Pre-surgery radiation plus immunotherapy for mucosal melanoma
Part of Cancer clinical trials.
This Phase 2 trial tests giving radiation and immunotherapy before surgery for mucosal melanoma in the nose/sinuses or rectum. It may help shrink the tumor and improve outcomes while aiming to control the disease locally and in nearby areas.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed mucosal melanoma tumor seen on exam or imaging (nose/sinuses or rectum).
- Your scans show no distant spread (no metastases).
- You are planning to receive a combination immunotherapy regimen (such as ipilimumab and nivolumab, or nivolumab and relatlimab).
- You are age 18 or older and can understand and sign informed consent.
- Your health status is good enough for treatment (ECOG 3 or less).
- You cannot have had prior radiation to the same area where the study radiation would be given.
- If you could get pregnant (or if you have a partner who could), you must agree to reliable birth control during the study and after radiation (RT is harmful to a pregnancy).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemo drugs (paclitaxel polymersomes, carboplatin) and an immunotherapy (adebelimab) before surgery for people with mucosal melanoma that can be removed. The goal is to see if this treatment shrinks the tumor and improves outcomes.
This trial studies whether giving pembrolizumab (an immunotherapy) together with a targeted form of radiation can help after surgery for mucosal melanoma. It aims to lower the chance of the cancer coming back and improve outcomes in people whose tumor was removed.
This trial studies how well two medicines—axitinib and nivolumab—work for people with advanced melanoma that starts in moist “mucosal” areas (like the mouth, nose, throat, or bowel). It may help shrink tumors and control the disease by boosting the immune system and targeting tumor growth.
This trial tests whether a combination of two immunotherapy drugs (nivolumab and relatlimab) can clear tiny amounts of cancer cells that remain after surgery in people with high-risk melanoma. It aims to prevent the cancer from coming back.
This trial tests whether giving two drugs (SHR-1701 and famitinib) before surgery, followed by additional treatment based on how well the tumor responds, can help patients with mucosal melanoma (a rare skin cancer in moist areas like the mouth or nose). The goal is to shrink the tumor and improve outcomes after surgery.
This trial tests two immunotherapy drugs, ipilimumab and nivolumab, given before surgery for people whose melanoma has come back after previous anti-PD1 treatment. The goal is to see if this combination can shrink the tumor and help prevent future recurrence.
Hear when a new Sinonasal Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.